메뉴 건너뛰기




Volumn 138, Issue 6, 2016, Pages 1494-1505

Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition

Author keywords

AZD4547; BGJ398; FGFR; liver cancer; MAPK

Indexed keywords

AZD 4547; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INFIGRATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 13; MYC PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

EID: 84954371320     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29893     Document Type: Article
Times cited : (27)

References (55)
  • 2
    • 63049133092 scopus 로고    scopus 로고
    • Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
    • Altekruse SF, McGlynn KA, Reichman ME., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 9: 1485-91.
    • (2009) J Clin Oncol , vol.9 , pp. 1485-1491
    • Altekruse, S.F.1    McGlynn, K.A.2    Reichman, M.E.3
  • 3
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V, et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 4: 378-90.
    • (2008) N Engl J Med , vol.4 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 4
    • 39149123547 scopus 로고    scopus 로고
    • Clinical application of the 70-gene profile: The MINDACT trial
    • Cardoso F, Van't Veer L, Rutgers E, et al., Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 5: 729-35.
    • (2008) J Clin Oncol , vol.5 , pp. 729-735
    • Cardoso, F.1    Van'T Veer, L.2    Rutgers, E.3
  • 5
    • 39149113165 scopus 로고    scopus 로고
    • Development of the 21-gene assay and its application in clinical practice and clinical trials
    • Sparano JA, Paik S., Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 5: 721-8.
    • (2008) J Clin Oncol , vol.5 , pp. 721-728
    • Sparano, J.A.1    Paik, S.2
  • 6
    • 79952438796 scopus 로고    scopus 로고
    • Genetics: An 18-gene signature (ColoPrint(R)) for colon cancer prognosis
    • Tan IB, Tan P., Genetics: an 18-gene signature (ColoPrint(R)) for colon cancer prognosis. Nat Rev Clin Oncol 2011; 3: 131-3.
    • (2011) Nat Rev Clin Oncol , vol.3 , pp. 131-133
    • Tan, I.B.1    Tan, P.2
  • 7
    • 41649114164 scopus 로고    scopus 로고
    • Enabling personalized cancer medicine through analysis of gene-expression patterns
    • van't Veer LJ, Bernards R., Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 7187: 564-70.
    • (2008) Nature , vol.7187 , pp. 564-570
    • Van'T Veer, L.J.1    Bernards, R.2
  • 8
    • 70349739285 scopus 로고    scopus 로고
    • Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
    • Hoshida Y, Nijman SM, Kobayashi M, et al., Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 18: 7385-92.
    • (2009) Cancer Res , vol.18 , pp. 7385-7392
    • Hoshida, Y.1    Nijman, S.M.2    Kobayashi, M.3
  • 9
    • 0036234628 scopus 로고    scopus 로고
    • Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer
    • Lee JS, Thorgeirsson SS., Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002; 5: 1134-43.
    • (2002) Hepatology , vol.5 , pp. 1134-1143
    • Lee, J.S.1    Thorgeirsson, S.S.2
  • 10
    • 42049116522 scopus 로고    scopus 로고
    • Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells
    • Fuchs BC, Fujii T, Dorfman JD, et al., Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 7: 2391-9.
    • (2008) Cancer Res , vol.7 , pp. 2391-2399
    • Fuchs, B.C.1    Fujii, T.2    Dorfman, J.D.3
  • 11
    • 84863179793 scopus 로고    scopus 로고
    • Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines
    • Zhao H, Desai V, Wang J, et al., Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther 2012; 2: 503-13.
    • (2012) Mol Cancer Ther , vol.2 , pp. 503-513
    • Zhao, H.1    Desai, V.2    Wang, J.3
  • 12
    • 77949875878 scopus 로고    scopus 로고
    • IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
    • Tovar V, Alsinet C, Villanueva A, et al., IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010; 4: 550-9.
    • (2010) J Hepatol , vol.4 , pp. 550-559
    • Tovar, V.1    Alsinet, C.2    Villanueva, A.3
  • 13
    • 84876734918 scopus 로고    scopus 로고
    • Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
    • Finn RS, Aleshin A, Dering J, et al., Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013; 5: 1838-46.
    • (2013) Hepatology , vol.5 , pp. 1838-1846
    • Finn, R.S.1    Aleshin, A.2    Dering, J.3
  • 14
    • 84876048479 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer
    • Dieci MV, Arnedos M, Andre F, et al., Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-79.
    • (2013) Discov , vol.3 , pp. 264-279
    • Dieci, M.V.1    Arnedos, M.2    Andre, F.3
  • 15
    • 75149170979 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling: From development to cancer
    • Turner N, Grose R., Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 2: 116-29.
    • (2010) Nat Rev Cancer , vol.2 , pp. 116-129
    • Turner, N.1    Grose, R.2
  • 16
    • 21044443128 scopus 로고    scopus 로고
    • In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
    • Lee SH, Lopes de Menezes D, Vora J, et al., In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 10: 3633-41.
    • (2005) Clin Cancer Res , vol.10 , pp. 3633-3641
    • Lee, S.H.1    Lopes De Menezes, D.2    Vora, J.3
  • 17
    • 49649123154 scopus 로고    scopus 로고
    • BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
    • Hilberg F, Roth GJ, Krssak M, et al., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 12: 4774-82.
    • (2008) Cancer Res , vol.12 , pp. 4774-4782
    • Hilberg, F.1    Roth, G.J.2    Krssak, M.3
  • 18
    • 33645670595 scopus 로고    scopus 로고
    • Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor
    • Bhide RS, Cai ZW, Zhang YZ, et al., Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 7: 2143-6.
    • (2006) J Med Chem , vol.7 , pp. 2143-2146
    • Bhide, R.S.1    Cai, Z.W.2    Zhang, Y.Z.3
  • 19
    • 0033883776 scopus 로고    scopus 로고
    • SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
    • Laird AD, Vajkoczy P, Shawver LK, et al., SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 15: 4152-60.
    • (2000) Cancer Res , vol.15 , pp. 4152-4160
    • Laird, A.D.1    Vajkoczy, P.2    Shawver, L.K.3
  • 20
    • 84860120185 scopus 로고    scopus 로고
    • AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
    • Gavine PR, Mooney L, Kilgour E, et al., AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 8: 2045-56.
    • (2012) Cancer Res , vol.8 , pp. 2045-2056
    • Gavine, P.R.1    Mooney, L.2    Kilgour, E.3
  • 21
    • 80054900437 scopus 로고    scopus 로고
    • Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase
    • Guagnano V, Furet P, Spanka C, et al., Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 20: 7066-83.
    • (2011) J Med Chem , vol.20 , pp. 7066-7083
    • Guagnano, V.1    Furet, P.2    Spanka, C.3
  • 22
    • 84871527692 scopus 로고    scopus 로고
    • A phase i dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
    • Abstract LB-122
    • Wolf J, Camidge RD, Perez JM, et al., A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2012; 8: Abstract LB-122.
    • (2012) Cancer Res , pp. 8
    • Wolf, J.1    Camidge, R.D.2    Perez, J.M.3
  • 23
    • 0030834170 scopus 로고    scopus 로고
    • Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues
    • Hughes SE., Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 7: 1005-19.
    • (1997) J Histochem Cytochem , vol.7 , pp. 1005-1019
    • Hughes, S.E.1
  • 24
    • 84859528536 scopus 로고    scopus 로고
    • Physiology of FGF15/19
    • Jones SA., Physiology of FGF15/19. Adv Exp Med Biol 2012; 728: 171-82.
    • (2012) Adv Exp Med Biol , vol.728 , pp. 171-182
    • Jones, S.A.1
  • 25
    • 0037663483 scopus 로고    scopus 로고
    • Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
    • Holt JA, Luo G, Billin AN, et al., Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 13: 1581-91.
    • (2003) Genes Dev , vol.13 , pp. 1581-1591
    • Holt, J.A.1    Luo, G.2    Billin, A.N.3
  • 26
    • 0036086285 scopus 로고    scopus 로고
    • A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
    • Nicholes K, Guillet S, Tomlinson E, et al., A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 6: 2295-307.
    • (2002) Am J Pathol , vol.6 , pp. 2295-2307
    • Nicholes, K.1    Guillet, S.2    Tomlinson, E.3
  • 27
    • 37849029159 scopus 로고    scopus 로고
    • Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
    • Desnoyers LR, Pai R, Ferrando RE, et al., Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 1: 85-97.
    • (2008) Oncogene , vol.1 , pp. 85-97
    • Desnoyers, L.R.1    Pai, R.2    Ferrando, R.E.3
  • 28
    • 84866171951 scopus 로고    scopus 로고
    • Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
    • French DM, Lin BC, Wang M, et al., Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012; 5: e36713.
    • (2012) PLoS One , vol.5 , pp. e36713
    • French, D.M.1    Lin, B.C.2    Wang, M.3
  • 29
    • 79952497178 scopus 로고    scopus 로고
    • Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening
    • Sawey ET, Chanrion M, Cai C, et al., Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011; 3: 347-58.
    • (2011) Cancer Cell , vol.3 , pp. 347-358
    • Sawey, E.T.1    Chanrion, M.2    Cai, C.3
  • 30
    • 84871491773 scopus 로고    scopus 로고
    • FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor
    • Guagnano V, Kauffmann A, Wohrle S, et al., FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 12: 1118-33.
    • (2012) Cancer Discov , vol.12 , pp. 1118-1133
    • Guagnano, V.1    Kauffmann, A.2    Wohrle, S.3
  • 31
    • 34748917797 scopus 로고    scopus 로고
    • AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
    • Huynh H, Chow PK, Soo KC., AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 2007; 9: 2468-76.
    • (2007) Mol Cancer Ther , vol.9 , pp. 2468-2476
    • Huynh, H.1    Chow, P.K.2    Soo, K.C.3
  • 32
    • 33846846541 scopus 로고    scopus 로고
    • Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas
    • Zucman-Rossi J, Benhamouche S, Godard C, et al., Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007; 5: 774-80.
    • (2007) Oncogene , vol.5 , pp. 774-780
    • Zucman-Rossi, J.1    Benhamouche, S.2    Godard, C.3
  • 33
    • 77349092851 scopus 로고    scopus 로고
    • Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements
    • Hoshida Y, Toffanin S, Lachenmayer A, et al., Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 1: 35-51.
    • (2010) Semin Liver Dis , vol.1 , pp. 35-51
    • Hoshida, Y.1    Toffanin, S.2    Lachenmayer, A.3
  • 34
    • 46249085489 scopus 로고    scopus 로고
    • Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer
    • Coulouarn C, Factor VM, Thorgeirsson SS., Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008; 6: 2059-67.
    • (2008) Hepatology , vol.6 , pp. 2059-2067
    • Coulouarn, C.1    Factor, V.M.2    Thorgeirsson, S.S.3
  • 35
    • 42249087302 scopus 로고    scopus 로고
    • Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma
    • Woo HG, Park ES, Cheon JH, et al., Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Can Res 2008; 7: 2056-64.
    • (2008) Clin Can Res , vol.7 , pp. 2056-2064
    • Woo, H.G.1    Park, E.S.2    Cheon, J.H.3
  • 36
    • 40449099255 scopus 로고    scopus 로고
    • EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma
    • Yamashita T, Forgues M, Wang W, et al., EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 5: 1451-61.
    • (2008) Cancer Res , vol.5 , pp. 1451-1461
    • Yamashita, T.1    Forgues, M.2    Wang, W.3
  • 37
    • 35948981211 scopus 로고    scopus 로고
    • Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma
    • Wang SM, Ooi LL, Hui KM., Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Can Res 2007; 21: 6275-83.
    • (2007) Clin Can Res , vol.21 , pp. 6275-6283
    • Wang, S.M.1    Ooi, L.L.2    Hui, K.M.3
  • 38
    • 4444286417 scopus 로고    scopus 로고
    • Molecular-based prediction of early recurrence in hepatocellular carcinoma
    • Kurokawa Y, Matoba R, Takemasa I, et al., Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004; 2: 284-91.
    • (2004) J Hepatol , vol.2 , pp. 284-291
    • Kurokawa, Y.1    Matoba, R.2    Takemasa, I.3
  • 39
    • 0032822672 scopus 로고    scopus 로고
    • FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4
    • Xie MH, Holcomb I, Deuel B, et al., FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 10: 729-35.
    • (1999) Cytokine , vol.10 , pp. 729-735
    • Xie, M.H.1    Holcomb, I.2    Deuel, B.3
  • 40
    • 34247565954 scopus 로고    scopus 로고
    • Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members
    • Goetz R, Beenken A, Ibrahimi OA, et al., Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 9: 3417-28.
    • (2007) Mol Cell Biol , vol.9 , pp. 3417-3428
    • Goetz, R.1    Beenken, A.2    Ibrahimi, O.A.3
  • 41
    • 77949328590 scopus 로고    scopus 로고
    • FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation
    • Wu X, Ge H, Lemon B, et al., FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 8: 5165-70.
    • (2010) J Biol Chem , vol.8 , pp. 5165-5170
    • Wu, X.1    Ge, H.2    Lemon, B.3
  • 42
    • 33751115468 scopus 로고    scopus 로고
    • Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man
    • Lundasen T, Galman C, Angelin B, et al., Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 6: 530-6.
    • (2006) J Intern Med , vol.6 , pp. 530-536
    • Lundasen, T.1    Galman, C.2    Angelin, B.3
  • 43
    • 18244409687 scopus 로고    scopus 로고
    • Gene expression profiling predicts clinical outcome of breast cancer
    • Van 't Veer LJ, Dai H, van de Vijver MJ, et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 6871: 530-6.
    • (2002) Nature , vol.6871 , pp. 530-536
    • Van 'T Veer, L.J.1    Dai, H.2    Van De Vijver, M.J.3
  • 44
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    • Bokemeyer C, Bondarenko I, Makhson A, et al., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 5: 663-71.
    • (2009) J Clin Oncol , vol.5 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3
  • 45
    • 0033569406 scopus 로고    scopus 로고
    • Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
    • Golub TR, Slonim DK, Tamayo P, et al., Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 5439: 531-7.
    • (1999) Science , vol.5439 , pp. 531-537
    • Golub, T.R.1    Slonim, D.K.2    Tamayo, P.3
  • 46
    • 84933557723 scopus 로고    scopus 로고
    • Clinicopathological indices to predict hepatocellular carcinoma molecular classification
    • In Press
    • Tan PS, Nakagawa S, Goossens N, et al., Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int 2015, In Press.
    • (2015) Liver Int
    • Tan, P.S.1    Nakagawa, S.2    Goossens, N.3
  • 47
    • 84898989382 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design
    • Llovet JM, Hernandez-Gea V., Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Can Res 2014; 8: 2072-9.
    • (2014) Clin Can Res , vol.8 , pp. 2072-2079
    • Llovet, J.M.1    Hernandez-Gea, V.2
  • 48
    • 84954196911 scopus 로고    scopus 로고
    • Tissue diagnosis of hepatocellular carcinoma
    • S 73
    • Jain D., Tissue diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol 2014; S3:S67 -S 73.
    • (2014) J Clin Exp Hepatol , pp. S3S67
    • Jain, D.1
  • 49
    • 34948821192 scopus 로고    scopus 로고
    • FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver
    • Huang X, Yang C, Luo Y, et al., FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 10: 2501-10.
    • (2007) Diabetes , vol.10 , pp. 2501-2510
    • Huang, X.1    Yang, C.2    Luo, Y.3
  • 50
    • 84928706270 scopus 로고    scopus 로고
    • MTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
    • Scheller T, Hellerbrand C, Moser C, et al., mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer 2015; 112: 841-50.
    • (2015) Br J Cancer , vol.112 , pp. 841-850
    • Scheller, T.1    Hellerbrand, C.2    Moser, C.3
  • 51
    • 84888294592 scopus 로고    scopus 로고
    • Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma
    • Deshmukh M, Hoshida Y., Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma. Hepatology 2013; 6: 2207.
    • (2013) Hepatology , vol.6 , pp. 2207
    • Deshmukh, M.1    Hoshida, Y.2
  • 52
    • 56949101730 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
    • Ho HK, Pok S, Streit S, et al., Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 1: 118-27.
    • (2009) J Hepatol , vol.1 , pp. 118-127
    • Ho, H.K.1    Pok, S.2    Streit, S.3
  • 53
    • 84885587718 scopus 로고    scopus 로고
    • Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study
    • Llovet JM, Decaens T, Raoul JL, et al., Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 28: 3509-16.
    • (2013) J Clin Oncol , vol.28 , pp. 3509-3516
    • Llovet, J.M.1    Decaens, T.2    Raoul, J.L.3
  • 54
    • 41149122199 scopus 로고    scopus 로고
    • Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)
    • Cai ZW, Zhang Y, Borzilleri RM, et al., Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 6: 1976-80.
    • (2008) J Med Chem , vol.6 , pp. 1976-1980
    • Cai, Z.W.1    Zhang, Y.2    Borzilleri, R.M.3
  • 55
    • 84862285959 scopus 로고    scopus 로고
    • Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase
    • Norman RA, Schott AK, Andrews DM, et al., Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem 2012; 11: 5003-12.
    • (2012) J Med Chem , vol.11 , pp. 5003-5012
    • Norman, R.A.1    Schott, A.K.2    Andrews, D.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.